Extranodal NK-T-cell lymphoma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(5 intermediate revisions by 2 users not shown)
Line 7: Line 7:
Extranodal NK/T-cell lymphoma, nasal type must be diffrentiated from [[Wegener's granulomatosis|Wegner's granulomatosis]], [[Polymorphic]] reticulosis, and Midline malignant [[Lymphomas|lymphoma]]
Extranodal NK/T-cell lymphoma, nasal type must be diffrentiated from [[Wegener's granulomatosis|Wegner's granulomatosis]], [[Polymorphic]] reticulosis, and Midline malignant [[Lymphomas|lymphoma]]
==Differential Diagnosis==
==Differential Diagnosis==
Extranodal NK t-cell must be differentiated with other NK and T cell hematologic malignancies and EBV-associated T cell or NK cell lymphoprolifrative disorders.<ref name="KarubeAoki2008">{{cite journal|last1=Karube|first1=Kennosuke|last2=Aoki|first2=Ryosuke|last3=Nomura|first3=Yuko|last4=Yamamoto|first4=Kohei|last5=Shimizu|first5=Kay|last6=Yoshida|first6=Shirou|last7=Komatani|first7=Hideki|last8=Sugita|first8=Yasuo|last9=Ohshima|first9=Koichi|title=Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: Analysis of 490 cases|journal=Pathology International|volume=58|issue=2|year=2008|pages=89–97|issn=13205463|doi=10.1111/j.1440-1827.2007.02195.x}}</ref>
*Extranodal NK t-cell must be differentiated with other NK and T cell hematologic malignancies and EBV-associated T cell or NK cell lymphoprolifrative disorders.<ref name="KarubeAoki2008">{{cite journal|last1=Karube|first1=Kennosuke|last2=Aoki|first2=Ryosuke|last3=Nomura|first3=Yuko|last4=Yamamoto|first4=Kohei|last5=Shimizu|first5=Kay|last6=Yoshida|first6=Shirou|last7=Komatani|first7=Hideki|last8=Sugita|first8=Yasuo|last9=Ohshima|first9=Koichi|title=Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: Analysis of 490 cases|journal=Pathology International|volume=58|issue=2|year=2008|pages=89–97|issn=13205463|doi=10.1111/j.1440-1827.2007.02195.x}}</ref>


Extranodal NK-T-cell lymphoma must be differentiated from other diseases such as:<ref name="Hindawi">Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type. Hindawi Publishing Corporation. http://www.hindawi.com/journals/ah/2010/627401/. Accessed on February 19, 2016 </ref>
*Extranodal NK-T-cell lymphoma must be differentiated from other diseases such as:<ref name="Hindawi">Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type. Hindawi Publishing Corporation. http://www.hindawi.com/journals/ah/2010/627401/. Accessed on February 19, 2016 </ref><ref name="pmid58185232">{{cite journal| author=Kassel SH, Echevarria RA, Guzzo FP| title=Midline malignant reticulosis (so-called lethal midline granuloma). | journal=Cancer | year= 1969 | volume= 23 | issue= 4 | pages= 920-35 | pmid=5818523 | doi=10.1002/1097-0142(196904)23:4<920::aid-cncr2820230430>3.0.co;2-m | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5818523  }}</ref>
**[[NK cell lukemia]]
**[[Lymphomatoid granulomatosis]]
**[[Diffuse large B cell lymphoma|EBV-positive diffuse large B cell lymphoma, NOS]]
**[[Anaplastic large cell lymphoma]]
**Non specific inflammatory process
**[[Enteropathy associated T cell lymphoma]]
**[[Peripheral T cell lymphoma]]
**[[Hepatosplenic T cell lymphoma]]


*[[NK cell lukemia]]<ref name="pmid58185232">{{cite journal| author=Kassel SH, Echevarria RA, Guzzo FP| title=Midline malignant reticulosis (so-called lethal midline granuloma). | journal=Cancer | year= 1969 | volume= 23 | issue= 4 | pages= 920-35 | pmid=5818523 | doi=10.1002/1097-0142(196904)23:4<920::aid-cncr2820230430>3.0.co;2-m | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5818523  }}</ref>
*Extranodal NK-T cell lymphoma, nasal type shows aggresive lethal midline granuloma macroscopicaly so it must be differentiated from diseases such as:<ref name="pmid5818523">{{cite journal| author=Kassel SH, Echevarria RA, Guzzo FP| title=Midline malignant reticulosis (so-called lethal midline granuloma). | journal=Cancer | year= 1969 | volume= 23 | issue= 4 | pages= 920-35 | pmid=5818523 | doi=10.1002/1097-0142(196904)23:4<920::aid-cncr2820230430>3.0.co;2-m | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5818523  }}</ref>
*[[Lymphomatoid granulomatosis]]
**[[Wegener's granulomatosis|Wegner's granulomatosis]]
*[[Diffuse large B cell lymphoma|EBV-positive diffuse large B cell lymphoma, NOS]]
**[[Polymorphic]] reticulosis
*[[Anaplastic large cell lymphoma]]
**Midline malignant [[Lymphomas|lymphoma]]
* Non specific inflammatory process
*[[Enteropathy associated T cell lymphoma]]
*[[Peripheral T cell lymphoma]]
*[[Hepatosplenic T cell lymphoma]]
 
Extranodal NK-T cell lymphoma, nasal type shows aggresive lethal midline granuloma macroscopicaly so it must be differentiated from diseases such as:<ref name="pmid5818523">{{cite journal| author=Kassel SH, Echevarria RA, Guzzo FP| title=Midline malignant reticulosis (so-called lethal midline granuloma). | journal=Cancer | year= 1969 | volume= 23 | issue= 4 | pages= 920-35 | pmid=5818523 | doi=10.1002/1097-0142(196904)23:4<920::aid-cncr2820230430>3.0.co;2-m | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5818523  }}</ref>
 
* [[Wegener's granulomatosis|Wegner's granulomatosis]]
* [[Polymorphic]] reticulosis
* Midline malignant [[Lymphomas|lymphoma]]


=== Differentiating extranodal NK T-cell  from other hematologic malignancies by immunophenotype and EBV infection: ===
=== Differentiating extranodal NK T-cell  from other hematologic malignancies by immunophenotype and EBV infection: ===
Extranodal NK T-cell lymphoma express [[CD56]] on its surface accompanied with [[EBV]] infection.
{| style="border: 0px; font-size: 90%; margin: 3px; width:600px"
{| style="border: 0px; font-size: 90%; margin: 3px; width:600px"
| valign="top" |
| valign="top" |
|+
|+
'''Malignancies based on immunophenotype and EBV infection'''
'''Malignancies based on immunophenotype and EBV infection'''
!style="background: #4479BA; width: 250px;" | {{fontcolor|#FFF|Disease}}
! style="background: #4479BA; width: 250px;" |{{fontcolor|#FFF|Disease}}
!style="background: #4479BA; width: 250px;" | {{fontcolor|#FFF|immunophenotype}}
! style="background: #4479BA; width: 250px;" |{{fontcolor|#FFF|Immunophenotype}}
!style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|EBV}}
! style="background: #4479BA; width: 100px;" |{{fontcolor|#FFF|EBV}}
|-
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[NK cell leukemia]]
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[NK cell leukemia]]
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD16+
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD16]]+
|style="padding: 5px 5px; background: #F5F5F5; align="center" |+
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | +
|-
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Lymphomatoid granulomatosis]]
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Lymphomatoid granulomatosis]]
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD20+
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD20]]+
|style="padding: 5px 5px; background: #F5F5F5; align="center" |+
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | +
|-
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Diffuse large B cell lymphoma|EBV-positive diffuse large B cell lymphoma, NOS]]  
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Diffuse large B cell lymphoma|EBV-positive diffuse large B cell lymphoma, NOS]]
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD20+ & CD76+
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD20]]+ [[CD76]]+
|style="padding: 5px 5px; background: #F5F5F5; align="center" |+
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | +
|-
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Peripheral T cell lymphoma|Peripheral T cell lymphoma, unspecified]]  
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Peripheral T cell lymphoma|Peripheral T cell lymphoma, unspecified]]
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD3+ & CD56-
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD3 (immunology)|CD3]]+ [[CD56]]-
|style="padding: 5px 5px; background: #F5F5F5; align="center" |-
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | -
|-
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Anaplastic large cell lymphoma, ALK positive|Anaplastic large cell lymphoma]]
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Anaplastic large cell lymphoma, ALK positive|Anaplastic large cell lymphoma]]
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD30+
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD30]]+
|style="padding: 5px 5px; background: #F5F5F5; align="center" |-
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | -
|-
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Hepatosplenic T cell lymphoma]]  
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Hepatosplenic T cell lymphoma]]
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD2+ & CD7+&CD3+
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD2]]+   [[CD70|CD7]]+ [[CD3 (immunology)|CD3]]+
|style="padding: 5px 5px; background: #F5F5F5; align="center" |-
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | -
|}
|}


Latest revision as of 15:25, 16 September 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2] Sowminya Arikapudi, M.B,B.S. [3]

Overview

Extranodal NK-T-cell lymphoma must be differentiated from other diseases such as NK cell lukemia, lymphomatoid granulomatosis, EBV-positive diffuse large B cell lymphoma, NOS, anaplastic large cell lymphoma, non specific inflammatory process, enteropathy associated T cell lymphoma, peripheral T cell lymphoma, hepatosplenic T cell lymphoma

Extranodal NK/T-cell lymphoma, nasal type must be diffrentiated from Wegner's granulomatosis, Polymorphic reticulosis, and Midline malignant lymphoma

Differential Diagnosis

  • Extranodal NK t-cell must be differentiated with other NK and T cell hematologic malignancies and EBV-associated T cell or NK cell lymphoprolifrative disorders.[1]
  • Extranodal NK-T cell lymphoma, nasal type shows aggresive lethal midline granuloma macroscopicaly so it must be differentiated from diseases such as:[4]

Differentiating extranodal NK T-cell from other hematologic malignancies by immunophenotype and EBV infection:

Extranodal NK T-cell lymphoma express CD56 on its surface accompanied with EBV infection.

Malignancies based on immunophenotype and EBV infection
Disease Immunophenotype EBV
NK cell leukemia CD16+ +
Lymphomatoid granulomatosis CD20+ +
EBV-positive diffuse large B cell lymphoma, NOS CD20+ CD76+ +
Peripheral T cell lymphoma, unspecified CD3+ CD56- -
Anaplastic large cell lymphoma CD30+ -
Hepatosplenic T cell lymphoma CD2+ CD7+ CD3+ -

References

  1. ↑ Karube, Kennosuke; Aoki, Ryosuke; Nomura, Yuko; Yamamoto, Kohei; Shimizu, Kay; Yoshida, Shirou; Komatani, Hideki; Sugita, Yasuo; Ohshima, Koichi (2008). "Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: Analysis of 490 cases". Pathology International. 58 (2): 89–97. doi:10.1111/j.1440-1827.2007.02195.x. ISSN 1320-5463.
  2. ↑ Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type. Hindawi Publishing Corporation. http://www.hindawi.com/journals/ah/2010/627401/. Accessed on February 19, 2016
  3. ↑ Kassel SH, Echevarria RA, Guzzo FP (1969). "Midline malignant reticulosis (so-called lethal midline granuloma)". Cancer. 23 (4): 920–35. doi:10.1002/1097-0142(196904)23:4<920::aid-cncr2820230430>3.0.co;2-m. PMID 5818523.
  4. ↑ Kassel SH, Echevarria RA, Guzzo FP (1969). "Midline malignant reticulosis (so-called lethal midline granuloma)". Cancer. 23 (4): 920–35. doi:10.1002/1097-0142(196904)23:4<920::aid-cncr2820230430>3.0.co;2-m. PMID 5818523.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Extranodal_NK-T-cell_lymphoma_differential_diagnosis&oldid=1581847"